^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | TTI-101 oral (STAT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2095 / 13 - Selective inhibition of the STAT3 pathway suppresses K-ras mutant lung tumorigenesis
Published date:
03/09/2022
Excerpt:
...we tested the anti-tumor ability of TTI-101, a selective STAT3 inhibitor, in a STAT3 addicted lung cancer cell line (MDA-F471) and in a transgenic mouse model of KM-LUAD (CCSPCre/LSL-KrasG12D, CC-LR)....TTI-101 therapy significantly reduced the tumor burden compared to ICB. TTI-101 also reduced the number of proliferating cells within tumors....Our studies show that TTI-101 can reduce K-ras driven tumor cell proliferation in vitro and in vivo, suggesting STAT3 inhibition as an alternative preventive and therapeutic modality for KM-LUAD.
